759 IMPACT OF ENTECAVIR VERSUS LAMIVUDINE ON HEPATIC COVALENTLY CLOSED-CIRCULAR DNA AND TOTAL HEPATIC HBVDNA IN NUCLEOSIDE-NAÏVE HBeAg POSITIVE CHRONIC HEPATITIS B PATIENTS

S. Bowden,S.A. Locarnini,T.-T. Chang,You‐Chen Chao,Kwang‐Hyub Han,Robert G. Gish,RA de Man,Cyril Llamoso,Hong Tang

DOI: https://doi.org/10.1016/s0168-8278(13)60761-8

IF: 25.7

2013-01-01

Journal of Hepatology

Abstract:POSTERS(Figure 1A).The HBeAg loss rate and mean HBeAg decline value from baseline were both significantly higher in the combination therapy group than in the NUC group at 48 weeks (42.1% vs. 10.7%,P = 0.002; 0.42 vs. 0.22 log 10 s/co, P = 0.004).The mean HBsAg decline value from baseline was also higher in the combination therapy group than in the monotherapy group at 48 weeks (1.06 vs. -0.09log 10 IU/mL, P < 0.001; Figure 1B).Two subjects in the combination therapy group achieved HBsAg seroconversion.There was no difference in rate of AEs between the two groups.Conclusions: Adding Peg-IFNa-2a on NUC therapy is well-tolerated and can improve HBeAg serconversion and qHBsAg decline in HBeAg-positive CHB patients who have achieved virological response with NUC therapy, which made it possible to shorten the treatment duration in these population.